Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 16/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.40 |
| ▸ | KDM5A | P29375 | 4/20 | 0.40 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 13/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196628 | 0.76 | ALDH1A1 (0.43) | MAPT | |
| SCHEMBL1654500 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL274867 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL2014792 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL14798059 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL380888 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL19816798 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL174463 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL2485369 | 0.75 | LMNA (0.63) | ABCC4MAPT | |
| SCHEMBL17744969 | 0.75 | LMNA (0.63) | ABCC4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | claimed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | claimed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | claimed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | EPHX2 4491/4885KDM4C 3859/4885PHF8 1933/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | EPHX2 4491/4885KDM4C 3859/4885PHF8 1933/4885 |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | EPHX2 4657/4885KDM4C 4006/4885PHF8 2030/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | EPHX2 4657/4885KDM4C 4006/4885PHF8 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.